200 related articles for article (PubMed ID: 1552641)
1. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
Hillner BE; Smith TJ; Desch CE
JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
[TBL] [Abstract][Full Text] [Related]
2. Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.
Hillner BE; Smith TJ; Desch CE
Pharmacoeconomics; 1994 Aug; 6(2):114-26. PubMed ID: 10147437
[TBL] [Abstract][Full Text] [Related]
3. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse.
Desch CE; Lasala MR; Smith TJ; Hillner BE
J Clin Oncol; 1992 Feb; 10(2):200-9. PubMed ID: 1531067
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
Uyl-de Groot CA; Hagenbeek A; Verdonck LF; Löwenberg B; Rutten FF
Bone Marrow Transplant; 1995 Sep; 16(3):463-70. PubMed ID: 8535321
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
7. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients.
Lee JH; Glick HA; Hayman JA; Solin LJ
J Clin Oncol; 2002 Jun; 20(11):2713-25. PubMed ID: 12039934
[TBL] [Abstract][Full Text] [Related]
8. New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer.
Lucey C; Westphal JR
South Med J; 1998 Feb; 91(2):196-201. PubMed ID: 9496875
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
Messori A; Bonistalli L; Costantini M; Alterini R
Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
[TBL] [Abstract][Full Text] [Related]
11. Autologous bone marrow transplantation for metastatic breast cancer.
Saez RA; Selby GB; Slease RB; Epstein RB; Mandanas RA; Confer DL
J Okla State Med Assoc; 1994 Sep; 87(9):405-10. PubMed ID: 7996314
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
13. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
[TBL] [Abstract][Full Text] [Related]
15. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
Desch CE; Hillner BE; Smith TJ; Retchin SM
J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
[TBL] [Abstract][Full Text] [Related]
16. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
18. Autologous bone marrow transplantation for adult acute leukemia.
Ball ED; Rybka WB
Hematol Oncol Clin North Am; 1993 Feb; 7(1):201-31. PubMed ID: 8449859
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out.
Smith GA; Henderson IC
Important Adv Oncol; 1995; ():201-14. PubMed ID: 7672807
[No Abstract] [Full Text] [Related]
[Next] [New Search]